Sandoz Launches Pyzchiva® in the US, Expanding Biosimilar Access

Sandoz, a global leader in generic and biosimilar medicines, has officially launched Pyzchiva® (ustekinumab-ttwe) in the US, marking a significant milestone in expanding access to affordable biologic treatments. Developed by Samsung Bioepis and commercialized by Sandoz, Pyzchiva® is approved by the FDA for the same indications as its reference medicine, Stelara®. This launch builds on Sandoz’s strategy to strengthen its position in the US biosimilars market following the introduction of Hyrimoz® in 2023.

With Pyzchiva®, patients now have a more cost-effective option for managing chronic autoimmune diseases, such as psoriasis and psoriatic arthritis. The medication offers flexible dosing options and extended stability, including re-refrigeration capabilities, setting it apart from the reference drug. Leah M. Howard, President of the National Psoriasis Foundation, emphasized the importance of biosimilars in making critical treatments more accessible. Sandoz has also introduced patient support resources, including insurance assistance, self-injection training, and a co-pay program. As part of its commercialization agreement with Samsung Bioepis, Sandoz will distribute Pyzchiva® across multiple markets, reinforcing its global leadership in biosimilars.

Explore the global impact of Sandoz and Henlius’ collaboration on ipilimumab biosimilars.